Get the latest news, insights, and market updates on PCRX (Pacira BioSciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 18th at 1:30PM GMT (8:30AM ET).37th Annual Piper Sandler Healthcare Conference on Tuesday, December 2nd at Nov 11, 2025 - $PCRX
Pacira: Q3 Earnings Snapshot
PCRX) on Thursday reported third-quarter net income of $5.4 million. The Brisbane, California-based company said it had net income of 12 cents per share. Earnings, adjusted for one-time gains and costs, came to 70 cents per share. Nov 6, 2025 - $PCRX
Pacira (PCRX) Tops Q3 Earnings Estimates
Pacira (PCRX) delivered earnings and revenue surprises of +7.69% and -1.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 6, 2025 - $PCRX
Pacira (PCRX) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Pacira (PCRX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Nov 6, 2025 - $PCRX
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quarter 2025 Financia Nov 6, 2025 - $PCRX
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
-- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has concluded patient enrollment in Part A of its Phase 2 ASCEND study evaluating PCRX-201 (e Nov 5, 2025 - $PCRX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple